tradingkey.logo
tradingkey.logo
Search

Boston Scientific reports above-consensus Q4 results, provides outlook

Investing.comFeb 5, 2025 12:28 PM
facebooktwitterlinkedin
View all comments(0)

Investing.com -- Boston Scientific (NYSE:BSX) reported fiscal Q4 2024 results that surpassed analyst expectations.

The company's shares swung between gains and losses in premarket trading Wednesday.

The company reported earnings per share (EPS) of $0.70, topping analyst expectations of $0.66. Revenue for the period came in at $4.56 billion, also exceeding the consensus estimate of $4.41 billion.

"2024 was one of the best years in the history of Boston Scientific, fueled by our innovative portfolio, the launch of our FARAPULSE Pulsed Field Ablation System as well as significant clinical achievements and commercial excellence across businesses and regions," said Mike Mahoney, chairman and CEO of Boston Scientific.

"We have a strong foundation for growth, and I am incredibly grateful for our talented global team and the opportunity to continue transforming the lives of millions of patients around the world."

For the first quarter, the company expects adjusted EPS between $0.66 and $0.68, in line with the consensus estimate of $0.66. Net sales on a reported basis are projected to grow between 17% and 19% and approximately 14% to 16% on an organic basis.

For the full year 2025, Boston Scientific forecasts EPS in the range of $2.80 to $2.87, compared to the consensus estimate of $2.81.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.